tetano
Editor, Senior Moderator
Mol Pharm. 2017 Jan 3;14(1):234-241. doi: 10.1021/acs.molpharmaceut.6b00826. Epub 2016 Nov 23.
[h=1]Macromolecular Prodrugs of Ribavirin: Structure-Function Correlation as Inhibitors of Influenza Infectivity.[/h] Riber CF[SUP]1[/SUP], Hinton TM[SUP]2[/SUP], Gajda P[SUP]3[/SUP], Zuwala K[SUP]3[/SUP], Tolstrup M[SUP]3[/SUP], Stewart C[SUP]2[/SUP], Zelikin AN[SUP]1,[/SUP][SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The requirement for new antiviral therapeutics is an ever present need. Particularly lacking are broad spectrum antivirals that have low toxicity. We develop such agents based on macromolecular prodrugs whereby both the polymer chain and the drug released from the polymer upon cell entry have antiviral effects. Specifically, macromolecular prodrugs were designed herein based on poly(methacrylic acid) and ribavirin. Structure-function parameter space was analyzed via the synthesis of 10 polymer compositions varied by molar mass and drug content. Antiviral activity was tested in cell culture against both low and high pathogenic strains of influenza. Lead compounds were successfully used to counter infectivity of influenza in chicken embryos. The lead composition with the highest activity against influenza was also active against another respiratory pathogen, respiratory syncytial virus, providing opportunity to potentially treat infection by the two pathogens with one antiviral agent. In contrast, structure-function activity against the herpes simplex virus was drastically different, revealing limitations of the broad spectrum antiviral agents based on macromolecular prodrugs.
[h=4]KEYWORDS:[/h] antiviral agents; drug delivery; herpes simplex virus; influenza; macromolecular prodrugs; respiratory syncytial virus
PMID: 28043136 DOI: 10.1021/acs.molpharmaceut.6b00826
[PubMed - in process]
[h=1]Macromolecular Prodrugs of Ribavirin: Structure-Function Correlation as Inhibitors of Influenza Infectivity.[/h] Riber CF[SUP]1[/SUP], Hinton TM[SUP]2[/SUP], Gajda P[SUP]3[/SUP], Zuwala K[SUP]3[/SUP], Tolstrup M[SUP]3[/SUP], Stewart C[SUP]2[/SUP], Zelikin AN[SUP]1,[/SUP][SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The requirement for new antiviral therapeutics is an ever present need. Particularly lacking are broad spectrum antivirals that have low toxicity. We develop such agents based on macromolecular prodrugs whereby both the polymer chain and the drug released from the polymer upon cell entry have antiviral effects. Specifically, macromolecular prodrugs were designed herein based on poly(methacrylic acid) and ribavirin. Structure-function parameter space was analyzed via the synthesis of 10 polymer compositions varied by molar mass and drug content. Antiviral activity was tested in cell culture against both low and high pathogenic strains of influenza. Lead compounds were successfully used to counter infectivity of influenza in chicken embryos. The lead composition with the highest activity against influenza was also active against another respiratory pathogen, respiratory syncytial virus, providing opportunity to potentially treat infection by the two pathogens with one antiviral agent. In contrast, structure-function activity against the herpes simplex virus was drastically different, revealing limitations of the broad spectrum antiviral agents based on macromolecular prodrugs.
[h=4]KEYWORDS:[/h] antiviral agents; drug delivery; herpes simplex virus; influenza; macromolecular prodrugs; respiratory syncytial virus
PMID: 28043136 DOI: 10.1021/acs.molpharmaceut.6b00826
[PubMed - in process]